Azacitidine
Progression Free Survival
Sun Yat-sen UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Progression Free Survival cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Karen-Lise Garm Spindler | Phase 2 | B |
Irinotecan Grupo Hospital de Madrid | Phase 2 | B |
Cetuximab Grupo Hospital de Madrid | Phase 2 | B |
Eloxatin Sun Yat-sen University | Phase 2 | B |
FLUOROURACILUM Karen-Lise Garm Spindler | Phase 2 | B |
Calcium folinate pentahydrate Karen-Lise Garm Spindler | Phase 2 | CCC |
mln9708 RenJi Hospital | N/A | D |
Tucidinostat Sun Yat-sen University | N/A | D |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →